SMTI vs. AVNS, ZJYL, INGN, LAKE, CLGN, APT, MLSS, NTRB, COCH, and RBOT
Should you be buying Sanara MedTech stock or one of its competitors? The main competitors of Sanara MedTech include Avanos Medical (AVNS), Jin Medical International (ZJYL), Inogen (INGN), Lakeland Industries (LAKE), CollPlant Biotechnologies (CLGN), Alpha Pro Tech (APT), Milestone Scientific (MLSS), Nutriband (NTRB), Envoy Medical (COCH), and Vicarious Surgical (RBOT). These companies are all part of the "surgical appliances & supplies" industry.
Sanara MedTech (NASDAQ:SMTI) and Avanos Medical (NYSE:AVNS) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, community ranking, media sentiment, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability.
Sanara MedTech has higher earnings, but lower revenue than Avanos Medical. Sanara MedTech is trading at a lower price-to-earnings ratio than Avanos Medical, indicating that it is currently the more affordable of the two stocks.
8.1% of Sanara MedTech shares are held by institutional investors. Comparatively, 95.2% of Avanos Medical shares are held by institutional investors. 54.1% of Sanara MedTech shares are held by insiders. Comparatively, 3.9% of Avanos Medical shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Avanos Medical received 65 more outperform votes than Sanara MedTech when rated by MarketBeat users. Likewise, 54.97% of users gave Avanos Medical an outperform vote while only 54.55% of users gave Sanara MedTech an outperform vote.
In the previous week, Avanos Medical had 9 more articles in the media than Sanara MedTech. MarketBeat recorded 11 mentions for Avanos Medical and 2 mentions for Sanara MedTech. Sanara MedTech's average media sentiment score of 1.88 beat Avanos Medical's score of -0.14 indicating that Sanara MedTech is being referred to more favorably in the media.
Sanara MedTech presently has a consensus price target of $44.00, indicating a potential upside of 44.12%. Given Sanara MedTech's stronger consensus rating and higher possible upside, equities analysts clearly believe Sanara MedTech is more favorable than Avanos Medical.
Sanara MedTech has a beta of 1.67, suggesting that its share price is 67% more volatile than the S&P 500. Comparatively, Avanos Medical has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500.
Sanara MedTech has a net margin of -7.19% compared to Avanos Medical's net margin of -9.15%. Avanos Medical's return on equity of 4.10% beat Sanara MedTech's return on equity.
Summary
Sanara MedTech beats Avanos Medical on 10 of the 18 factors compared between the two stocks.
Get Sanara MedTech News Delivered to You Automatically
Sign up to receive the latest news and ratings for SMTI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SMTI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sanara MedTech Competitors List
Related Companies and Tools
